ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,921 to 3,940 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Adherence Intervention vs Usual Care: Blood Pressure Medication Adherence470 of 887

396 of 843

6.0 points

1.3 to 10.7

1,730NCT03748420

Medication Adherence Clinical Decision Support

Donanemab vs Placebo: deaths from any cause16 of 853

10 of 874

0.7 points

-0.5 to 2.0

1,727NCT04437511

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Donanemab vs Placebo: serious adverse events148 of 853

138 of 874

1.6 points

-1.9 to 5.1

1,727NCT04437511

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

TRIP Patient Navigation Intervention vs Control- Usual Care: deaths from any cause16 of 1,175

14 of 550

-1.2 points

-2.9 to 0.1

1,725NCT03514433

Translating Research Into Practice: Patient Navigation for Breast Cancer

Vadadustat vs Darbepoetin Alfa: deaths from any cause139 of 861

139 of 862

0.0 points

-3.5 to 3.5

1,723NCT02680574

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Vadadustat vs Darbepoetin Alfa: serious adverse events504 of 861

488 of 862

1.9 points

-2.7 to 6.6

1,723NCT02680574

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

No Mobile Phone-administered Triage Tool vs Mobile Phone-administered Triage Tool: Proportion of Injured Patients Who Seek Clinical Follow-up Evaluation409 of 776

615 of 946

-12.3 points

-16.9 to -7.6

1,722NCT03805646

Mobile Phone-administered Triage Tool to Followup on Discharged Trauma Patients

GSK1437173A Group vs Placebo Group: Number of Subjects With Postherpetic Neuralgia (PHN)1 of 870

9 of 851

-0.9 points

-1.9 to -0.2

1,721NCT01610414

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

GSK1437173A Group vs Placebo Group: Number of Subjects With Confirmed Herpes Zoster (HZ) Episode49 of 870

135 of 851

-10.2 points

-13.2 to -7.3

1,721NCT01610414

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

GSK1437173A Group vs Placebo Group: Number of Subjects With Confirmed HZ-associated Complications3 of 870

13 of 851

-1.2 points

-2.3 to -0.3

1,721NCT01610414

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Baseline Period vs Intervention Period: Medication Escalations106 of 830

117 of 890

-0.4 points

-3.5 to 2.8

1,720NCT01070095

The Electronic Asthma Action Plan System for Implementation in Primary Care

Baseline Period vs Intervention Period: Asthma Control Assessment118 of 830

523 of 890

-44.5 points

-48.4 to -40.4

1,720NCT01070095

The Electronic Asthma Action Plan System for Implementation in Primary Care

Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Sustained QuantiFERON®-TB Gold Plus Assay (QFT) Conversion From a Negative to Positive Test Based on Positive QFT Test Results82 of 871

78 of 849

0.2 points

-2.5 to 3.0

1,720NCT04152161

Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection

Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Sustained QFT Conversion From a Negative to Positive Test Based on Positive QFT Test Results at 36-Months Follow-up or Discontinued Early74 of 871

73 of 849

-0.1 points

-2.8 to 2.6

1,720NCT04152161

Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection

Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Sustained QFT Conversion From a Negative to Positive Test Based on Positive QFT Test Results at 48-Months Follow-up or Discontinued Early82 of 871

78 of 849

0.2 points

-2.5 to 3.0

1,720NCT04152161

Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection

Boostrix+Fluarix Group vs Fluarix Boostrix Group: serious adverse events3 of 860

7 of 858

-0.5 points

-1.4 to 0.3

1,718NCT00385255

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: deaths from any cause1 of 885

0 of 833

0.1 points

-0.4 to 0.6

1,718NCT01499511

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: serious adverse events2 of 885

0 of 833

0.2 points

-0.3 to 0.8

1,718NCT01499511

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Hextend vs Standard of Care: Mortality42 of 805

81 of 909

-3.7 points

-6.1 to -1.3

1,714NCT00983281

Use of Hextend in Trauma

mRNA-1273.712 vs Placebo: Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2)4 of 858

8 of 853

-0.5 points

-1.4 to 0.4

1,711NCT06634797

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=197"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=197

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03748420-9cf14b96",
        "title": "Adherence Intervention vs Usual Care: Blood Pressure Medication Adherence",
        "summary": "470 of 887 against 396 of 843; risk difference 6.0 points, 95% interval 1.3 to 10.7; NCT03748420, Medication Adherence Clinical Decision Support",
        "record": "/library/comparisons/NCT03748420-9cf14b96",
        "nct_id": "NCT03748420",
        "kind": "outcome",
        "participants": 1730,
        "risk_difference": {
          "value": 0.06012509679153616,
          "lower": 0.012988719015422041,
          "upper": 0.1068851075770806
        },
        "group_1": "470 of 887",
        "group_2": "396 of 843",
        "difference": "6.0 points",
        "interval": "1.3 to 10.7",
        "trial_title": "Medication Adherence Clinical Decision Support"
      },
      {
        "id": "NCT04437511-deaths",
        "title": "Donanemab vs Placebo: deaths from any cause",
        "summary": "16 of 853 against 10 of 874; risk difference 0.7 points, 95% interval -0.5 to 2.0; NCT04437511, A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)",
        "record": "/library/comparisons/NCT04437511-deaths",
        "nct_id": "NCT04437511",
        "kind": "deaths",
        "participants": 1727,
        "risk_difference": {
          "value": 0.0073156794836369676,
          "lower": -0.004584620065177649,
          "upper": 0.019937572147416746
        },
        "group_1": "16 of 853",
        "group_2": "10 of 874",
        "difference": "0.7 points",
        "interval": "-0.5 to 2.0",
        "trial_title": "A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=198",
  "request_id": "WM9sZhHxyvNXaQ7F"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?